Company Overview of MedImmune, LLC
MedImmune, LLC, a biotechnology company, engages in the research, development, and commercialization of biological products, and therapeutic and preventive medicines for use in the areas of infectious diseases, oncology, respiratory diseases, inflammation, cardiovascular/gastrointestinal diseases, and neuroscience. Its products include Synagis, a monoclonal antibody that is used for the prevention of serious lower respiratory tract disease caused by RSV in children; FluMist, a nasal spray flu vaccine that is used for the active immunization of eligible individuals between 2 to 49 years of age against influenza disease caused by influenza virus subtypes A and B contained in the vaccine; and E...
One MedImmune Way
Gaithersburg, MD 20878
Founded in 1988
Key Executives for MedImmune, LLC
Chief Financial Officer and Senior Vice President
Executive Vice President of Operations
Chief Information Officer and Vice President
Compensation as of Fiscal Year 2012.
MedImmune, LLC Key Developments
MedImmune and NGM Biopharmaceuticals Announce Agreement to Discover and Develop Therapies for Diabetes and Obesity
Jun 17 13
AstraZeneca announced that MedImmune and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from NGM's enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity. EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1. EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis. NGM has established a proprietary platform capable of isolating and analysing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases. MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones. MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialisation of compounds resulting from the collaboration.
Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration. If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.
MedImmune, LLC Presents at 2013 BIO International Convention, Apr-23-2013 08:45 AM
Apr 18 13
MedImmune, LLC Presents at 2013 BIO International Convention, Apr-23-2013 08:45 AM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.
MedImmune, LLC Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013
Dec 19 12
MedImmune, LLC Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 . Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions